Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma

The assessment of measurable residual disease (MRD) in bone marrow has proven of prognostic relevance in patients with multiple myeloma (MM). Nevertheless, and unlike other hematologic malignancies, the use of MRD results to make clinical decisions in MM has been underexplored to date. In this retro...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinez-Lopez, Joaquin, Alonso, Rafael, Wong, Sandy W., Rios, Rafael, Shah, Nina, Ruiz-Heredia, Yanira, Sanchez-Pina, Jose Maria, Sanchez, Ricardo, Bahri, Natasha, Zamanillo, Irene, Poza, Maria, Buenache, Natalia, Encinas, Cristina, Juarez, Luis, Miras, Fatima, Collado, Luis, Barrio, Santiago, Martin, Thomas, Cedena, Maria Teresa, Wolf, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369640/
https://www.ncbi.nlm.nih.gov/pubmed/34404440
http://dx.doi.org/10.1186/s13045-021-01135-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369640/
https://www.ncbi.nlm.nih.gov/pubmed/34404440
http://dx.doi.org/10.1186/s13045-021-01135-w

Ejemplares similares